
Pharmacovigilance Signal Detection Framework
Detect and validate adverse event safety signals in pharmacovigilance datasets
What You Can Do
You systematically identify potential adverse event signals from large pharmacovigilance datasets using statistical disproportionality analysis, temporal trends, and stratified subgroup evaluation. Claude validates signals against case narratives, calculates confidence metrics, and prioritizes safety concerns by severity and frequency. You generate regulatory-compliant safety reports with actionable recommendations for clinical review teams.
Features
Calculate reporting ratios (ROR, PRR, EBGM) to identify adverse events occurring more frequently than expected for a drug-event pair
Identify emerging safety signals through time-series analysis, detecting when adverse event reporting accelerates or concentrates in specific periods
Evaluate signals across patient demographics, concomitant medications, dose ranges, and indication subgroups to identify vulnerable populations
Parse and evaluate individual case safety reports (ICSRs) to assess causality, severity, outcome, and dechallenge/rechallenge patterns
Identify signals correlated with specific concomitant medications or drug combinations that may potentiate adverse events
Rank signals by severity, frequency, clinical impact, and regulatory risk to focus investigation resources on highest-priority concerns
Produce FDA MedWatch, EMA periodic safety updates, and REMS compliance documentation with signal summary tables and recommendations
Verify signal detection methodology, validate statistical calculations, and confirm compliance with ICH-E2A/E2B guidelines
Example Output
Example 1: Disproportionality Signal Report
Signal: Acute Kidney Injury (Drug A)
- ROR: 2.85 (95% CI: 1.92-4.21)
- PRR: 3.12 (Chi-square: p<0.001)
- Case Count: 47 observed vs 16 expected
- Recommendation: INVESTIGATE — signal meets statistical threshold
Example 2: Subgroup Stratification
Acute Kidney Injury Signal Stratified by Age:
- Ages 65+: ROR 4.21 (n=28) — HIGH RISK
- Ages 50-64: ROR 2.15 (n=15) — MODERATE
- Ages <50: ROR 0.89 (n=4) — NO SIGNAL
Conclusion: Elderly population requires dose adjustment or enhanced monitoring
Example 3: Temporal Trend & Recommendation
QT Prolongation Cases Over 12 Months:
Jan-Mar: 3 cases | Apr-Jun: 7 cases | Jul-Sep: 14 cases | Oct-Dec: 22 cases
Trend: 18% monthly increase (p=0.003)
Recommendation: Add ECG screening to standard safety monitoring; evaluate label update for QT risk disclosure
What's Included
- Signal Detection Workflow Templates: Step-by-step procedures for systematic adverse event signal identification, validation, and escalation
- Statistical Validation Frameworks: Pre-configured calculations for ROR, PRR, EBGM, and other disproportionality metrics with confidence interval computation
- Risk Stratification Matrices: Decision support tools for severity assessment, population vulnerability evaluation, and clinical impact scoring
- Regulatory Reporting Templates: FDA MedWatch, EMA PSUSARs, and REMS documentation formats with automated summary table generation
- Case Evaluation Checklists: Quality assurance guides for case narrative assessment, causality evaluation (Naranjo/WHO-UMC), and outcome classification
Who It's For
- Pharmacovigilance Specialists
- Drug Safety Officers
- Regulatory Affairs Professionals
- Clinical Trial Safety Monitors
- Post-Market Surveillance Teams
Best For
- Post-market safety signal monitoring
- Adverse event signal investigation and validation
- Regulatory submission and periodic safety report preparation
- Clinical trial blinded safety reviews
- Drug interaction and subgroup safety analysis






